|
Characteristics of the patients included in the meta-analysis |
||||||
| Total |
% |
Control group |
% |
Intervention group |
% |
|
|
|
||||||
| Level of care |
||||||
| Primary care |
4505 |
57.8 |
2127 |
57.6 |
2378 |
58.1 |
| Specialised care |
3284 |
42.2 |
1567 |
42.4 |
1717 |
41.9 |
| Overall |
7789 |
100.0 |
3694 |
100.0 |
4095 |
100.0 |
| Kind of treatment |
||||||
| Pharmacological |
5706 |
73.3 |
2684 |
72.7 |
3022 |
73.8 |
| Non-pharmacological |
2083 |
26.7 |
1010 |
27.3 |
1073 |
26.2 |
| Overall |
7789 |
100.0 |
3694 |
100.0 |
4095 |
100.0 |
| Outcome assessed |
||||||
| Anxiety/depression |
1195 |
15.3 |
570 |
15.4 |
625 |
15.3 |
| Quality of life |
115 |
1.5 |
51 |
1.4 |
64 |
1.6 |
| Pain |
2074 |
26.6 |
980 |
26.5 |
1094 |
26.7 |
| Fatigue |
650 |
8.3 |
320 |
8.7 |
330 |
8.1 |
| Tender points |
1533 |
19.7 |
738 |
20.0 |
795 |
19.4 |
| Insomnia |
397 |
5.1 |
196 |
5.3 |
201 |
4.9 |
| Global function |
1825 |
23.4 |
839 |
22.7 |
986 |
24.1 |
| Overall |
7789 |
100.0 |
3694 |
100.0 |
4095 |
100.0 |
| Methodological quality |
||||||
| 1 to 2 |
595 |
7.6 |
289 |
7.8 |
306 |
7.5 |
| 3 to 4 |
3396 |
43.6 |
1577 |
42.7 |
1819 |
44.4 |
| 5 to 6 |
3798 |
48.8 |
1828 |
49.5 |
1970 |
48.1 |
| Overall |
7789 |
100.0 |
3694 |
100.0 |
4095 |
100.0 |
| Length of treatment (weeks) |
||||||
| 0 to 8 |
3644 |
46.8 |
1750 |
47.4 |
1894 |
46.3 |
| 09 to 16 |
3467 |
44.5 |
1678 |
45.4 |
1789 |
43.7 |
| 17 to 24 |
678 |
8.7 |
266 |
7.2 |
412 |
10.1 |
| Overall |
7789 |
100.0 |
3694 |
100.0 |
4095 |
100.0 |
| Age |
||||||
| 30 to 39 |
253 |
3.2 |
125 |
3.4 |
128 |
3.1 |
| 40 to 49 |
6662 |
85.5 |
3140 |
85.0 |
3522 |
86.0 |
| 50 to 59 |
874 |
11.2 |
429 |
11.6 |
445 |
10.9 |
| Overall |
7789 |
100.0 |
3694 |
100.0 |
4095 |
100.0 |
| Percentage of women |
||||||
| < 80 |
151 |
1.9 |
73 |
2.0 |
78 |
1.9 |
| 80 to 89 |
2258 |
29.0 |
1111 |
30.1 |
1147 |
28.0 |
| 90 to 99 |
2874 |
36.9 |
1297 |
35.1 |
1577 |
38.5 |
| 100 |
2506 |
32.2 |
1213 |
32.8 |
1293 |
31.6 |
| Overall |
7789 |
100.0 |
3694 |
100.0 |
4095 |
100.0 |
| Duration of the disorder (years) |
||||||
| 0 to 5 |
1459 |
25.3 |
710 |
26.3 |
749 |
24.5 |
| 6 to 10 |
2987 |
51.9 |
1344 |
49.7 |
1643 |
53.8 |
| 11 to 15 |
1310 |
22.8 |
649 |
24.0 |
661 |
21.7 |
| Overall |
5756 |
100.0 |
2703 |
100.0 |
3053 |
100.0 |
| Country |
||||||
| Germany |
410 |
5.3 |
206 |
5.6 |
204 |
5.0 |
| Belgium |
459 |
5.9 |
216 |
5.8 |
243 |
5.9 |
| Brasil |
278 |
3.6 |
132 |
3.6 |
146 |
3.6 |
| Canada |
1655 |
21.2 |
737 |
20.0 |
918 |
22.4 |
| Finland |
488 |
6.3 |
240 |
6.5 |
248 |
6.1 |
| Holland |
174 |
2.2 |
86 |
2.3 |
88 |
2.1 |
| Norway |
195 |
2.5 |
102 |
2.8 |
93 |
2.3 |
| Sweden |
254 |
3.3 |
126 |
3.4 |
128 |
3.1 |
| Switzerland |
276 |
3.5 |
135 |
3.7 |
141 |
3.4 |
| Turkey |
298 |
3.8 |
148 |
4.0 |
150 |
3.7 |
| USA |
3302 |
42.4 |
1566 |
42.4 |
1736 |
42.4 |
| Overall |
7789 |
100.0 |
3694 |
100.0 |
4095 |
100.0 |
| Year of publication |
||||||
| 1994 |
620 |
8.0 |
234 |
6.3 |
386 |
9.4 |
| 1995 |
178 |
2.3 |
86 |
2.3 |
92 |
2,.2 |
| 1996 |
1306 |
16.8 |
637 |
17.2 |
669 |
16.3 |
| 1997 |
38 |
0.5 |
18 |
0.5 |
20 |
0.5 |
| 1998 |
724 |
9.3 |
349 |
9.4 |
375 |
9.2 |
| 2000 |
207 |
2.7 |
102 |
2.8 |
105 |
2.6 |
| 2001 |
926 |
11.9 |
460 |
12.5 |
466 |
11.4 |
| 2002 |
780 |
10.0 |
372 |
10.1 |
408 |
10.0 |
| 2003 |
392 |
5.0 |
196 |
5.3 |
196 |
4.8 |
| 2004 |
1241 |
15.9 |
621 |
16.8 |
620 |
15.1 |
| 2005 |
1377 |
17.7 |
619 |
16.8 |
758 |
18.5 |
| Overall |
7789 |
100.0 |
3694 |
100.0 |
4095 |
100.0 |
Garcia-Campayo et al. Arthritis Research & Therapy 2008 10:R81 doi:10.1186/ar2455 |
||||||